#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17454	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2313	917.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1821	1821	T	1104	T,G,C	1099,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17454	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2313	917.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1555	1555	C	1123	C,T,A	1119,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30422	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4049	935.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1974	1974	A	1165	A,G	1164,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30422	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4049	935.6	0	.	n	.	0	C1344T	SNP	1344	1344	C	1981	1981	T	1128	T,C,G	867,259,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30422	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4049	935.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2608	2608	C	1079	C,A,G	1074,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30422	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4049	935.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2682	2682	A	1048	A,C	1046,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30422	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4049	935.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3234	3234	C	1075	C,A,T	1072,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30422	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4049	935.6	0	HET	.	.	.	G996A,T	.	996	996	G	1633	1633	G	1142	G,A,T	885,254,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30422	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4049	935.6	0	HET	.	.	.	G1834A	.	1834	1834	G	2471	2471	G	1073	G,A	769,303	.	.
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	27	2800	folP	852	852	99.88	folP.l15.c4.ctg.1	2092	166.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6184	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3942	195.6	1	SNP	p	S91F	0	.	.	271	273	TCC	846	848	TCC	243;243;240	T;C;C,A	243;243;239,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6184	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3942	195.6	1	SNP	p	D95G	0	.	.	283	285	GAC	858	860	GAC	235;234;234	G,C;A,T;C	234,1;233,1;234	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6184	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3942	195.6	1	SNP	p	D95N	0	.	.	283	285	GAC	858	860	GAC	235;234;234	G,C;A,T;C	234,1;233,1;234	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2234	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1832	152.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	655	657	ACC	244;245;245	A,G;C;C	242,1;244;244	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2234	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1832	152.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	853	855	CAC	291;292;293	C,T;A;C,G	289,2;292;292,1	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2234	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1832	152.0	0	.	p	.	0	E117K	NONSYN	349	351	GAA	889	891	AAA	270;272;276	A,G;A,G,T;A,C	269,1;270,1,1;275,1	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	2234	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1832	152.0	1	SNP	p	G45D	0	.	.	133	135	GGC	673	675	GGC	252;253;256	G,T;G;C	251,1;253;256	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1366	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1569	108.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3502	212.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1943	1945	GCA	280;282;285	G;C;A,G	280;282;284,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3502	212.5	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2426	2428	ATT	284;286;283	A;T;T,C	284;286;282,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3502	212.5	1	SNP	p	D86N	0	.	.	256	258	GAC	896	898	GAC	258;255;262	G;A;C,T	258;255;261,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3502	212.5	1	SNP	p	S87W	0	.	.	259	261	AGT	899	901	AGT	262;262;261	A,C;G;T	260,2;262;261	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3502	212.5	1	SNP	p	S87I	0	.	.	259	261	AGT	899	901	AGT	262;262;261	A,C;G;T	260,2;262;261	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3502	212.5	1	SNP	p	S87R	0	.	.	259	261	AGT	899	901	AGT	262;262;261	A,C;G;T	260,2;262;261	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5968	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3502	212.5	1	SNP	p	S88P	0	.	.	262	264	TCC	902	904	TCC	265;265;266	T,C;C;C,T,G	264,1;265;264,1,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5254	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3157	207.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1774	1776	GGC	295;294;296	G;G;C,A	295;294;295,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1493	1495	GCA	284;284;284	G,C;C;A	283,1;284;284	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1496	1498	ATC	284;280;284	A,G,T;T,A,G;C	282,1,1;278,1,1;284	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1508	1510	GTG	284;283;282	G,C;T,G;G,C	283,1;282,1;280,1	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1508	1510	GTG	284;283;282	G,C;T,G;G,C	283,1;282,1;280,1	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2012	2014	ACC	314;310;308	A,G,T;C,T;C	311,2,1;309,1;308	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2066	2068	GCG	290;290;285	G;C,G;G	290;289,1;285	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2066	2068	GCG	290;290;285	G;C,G;G	290;289,1;285	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2189	2191	GGT	291;293;290	G;G;T	291;293;290	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2198	2200	GGC	291;289;287	G;G;C	291;289;287	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	5082	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2815	224.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2216	2218	CCG	282;278;277	C,A;C,T;G,C	281,1;277,1;276,1	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6602	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3571	230.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2226	153.5	0	.	p	.	0	S22G	NONSYN	64	66	AGC	608	610	GGC	191;192;192	G,A;G;C	190,1;191;192	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2226	153.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	790	790	C	220	C,G	219,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3444	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1769	236.0	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	855	857	CAA	295;304;307	C,A;A,T;A	293,2;303,1;307	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3444	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1769	236.0	0	.	p	.	0	E212G	NONSYN	634	636	GAA	1062	1064	GGT	273;272;275	G,T;G,A;T,A	271,2;271,1;274,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3444	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1769	236.0	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1065	1067	GAT	273;275;276	G,A;A;T,G	272,1;275;275,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3444	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1769	236.0	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1071	1073	GCT	277;278;282	G;C;T,G	277;278;281,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3444	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1769	236.0	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1080	1082	ATG	288;287;287	A;T;G,T	288;287;286,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3444	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1769	236.0	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1197	1199	AAG	313;312;312	A;A;G	313;312;312	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3444	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1769	236.0	1	SNP	p	G120K	0	.	.	358	360	GGC	786	788	GGC	259;259;260	G,A;G,C;C	258,1;258,1;260	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	12216	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5396	282.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2240	2242	CAT	312;310;313	C;A,C;T	312;309,1;313	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1844	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1376	166.2	1	SNP	p	V57M	0	.	.	169	171	GTG	727	729	GTG	355;352;352	G,T;T;G	354,1;352;352	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
